The face of the patent is not the “Whole Story”: determining effective life of a pharmaceutical patent in the United States

Anne Marie Clark، نويسنده , , Heidi Berven، نويسنده ,

روزنامه با شماره پیاپی سال 2004

13

283

295

Patent term , Correction certificates , Pharmaceutical patents , FDA , Maintenance fees , interference , Market exclusivity , OTC switches , Hatch–Waxman , ANDA exclusivity , Pediatric exclusivity , Terminal disclaimers , Infringement , NCE exclusivity , Patent expiry , Orphan drug exclusivity

World Patent Information

2004

World Patent Information

274070